Narrowing in on Cardiovascular Disease: The Atheroprotective Role of Peroxisome Proliferator-Activated Receptor γ

Trends in Cardiovascular Medicine

Volumn 18, Issue 2, 2008, Pages 39-44

  Gerry, Jon M ^a,b   Pascual, Gabriel ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CX3CR1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR AP 1;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CHRONIC INFLAMMATION; GENE SEQUENCE; GENE TARGETING; HUMAN; MACROPHAGE ACTIVATION; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSACTIVATION;

ATHEROSCLEROSIS; HUMANS; INFLAMMATION; MACROPHAGE ACTIVATION; MACROPHAGES; PPAR GAMMA; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 39549119096     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcm.2007.12.001     Document Type: Review

References (40)

1. Barlic J., Zhang Y., Foley J., and Murphy P. Oxidized lipid-driven chemokine receptor switch, CCR2 to CX3CR1, mediates adhesion of human macrophages to coronary artery smooth muscle cells through a peroxisome proliferator-activated receptor gamma-dependent pathway. Circulation 114 (2006) 807-819
2. Bouhlel M., Derudas B., Rigamonti E., et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab 6 (2007) 137-143
3. Chawla A., Barak Y., Nagy L., et al. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 7 (2001) 48-52
4. Chung S., Kang B., Kim S., et al. Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-kappa B. J Biol Chem 275 (2000) 32681-32687
5. Combadiere C., Potteaux S., Gao J., et al. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 107 (2003) 1009-1016
6. Cushing S., Berliner J., Valente A., et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A 87 (1990) 5134-5140
7. Delerive P., Martin-Nizard F., Chinetti G., et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 85 (1999) 394-402
8. Feige J., Gelman L., Tudor C., et al. Fluorescence imaging reveals the nuclear behavior of peroxisome proliferator-activated receptor/retinoid X receptor heterodimers in the absence and presence of ligand. J Biol Chem 280 (2005) 17880-17890
9. Fong L., Fong T., and Cooper A. Inhibition of lipopolysaccharide-induced interleukin-1 beta mRNA expression in mouse macrophages by oxidized low density lipoprotein. J lipid Res 32 (1991) 1899-1910
10. Fonseca V. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus. Am J Med 120 (2007) S18-S25
11. Geissmann F., Jung S., and Littman D. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19 (2003) 71-82
12. Ghosh S., and Karin M. Missing pieces in the NF-kappaB puzzle. Cell 109 (2002) S81-S96
13. Glass C., and Witztum J. Atherosclerosis. The road ahead. Cell 104 (2001) 503-516
14. Guenther M., Lane W., Fischle W., et al. A Core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness. Genes Dev 14 (2000) 1048-1057
15. Han K., Tangirala R., Green S., and Quehenberger O. Chemokine receptor CCR2 expression and monocyte chemoattractant protein-1-mediated chemotaxis in human monocytes. A regulatory role for plasma LDL. Arterioscler Thromb Vasc Biol 18 (1998) 1983-1991
16. Han K., Chang M., Boullier A., et al. Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor g. J Clin Invest 106 (2000) 793-802
17. Huang J., Welch J., Ricote M., et al. Interleukin-4-dependent production of PPAR-g ligands in macrophages by 12/15-lipoxygenase. Nature 400 (1999) 378-382
18. Larsen T., Toubro S., and Astrup A. PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy?. Int J Obes Relat Metab Disord 27 (2003) 147-161
19. Li A., Brown K., Silvestre M., et al. Peroxisome proliferator-activated receptor g ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J CIin Invest 106 (2000) 523-531
20. Li M., Pascual G., and Glass C. Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Mol Cell Biol 20 (2000) 4699-4707
21. Li A., Binder C., Gutierrez A., et al. Differential inhibition of macrophage foam cell formation and atherosclerosis in mice by PPAR a, b/d, and g. J Clin Invest 114 (2004) 1564-1576
22. Lincoff, Wolski K., Nicholls S., and Nissen S. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298 (2007) 1180-1188
23. Nagy L., Tontonoz P., Alvarez J., et al. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 93 (1998) 229-240
24. Nissen S., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
25. Odegaard J., Ricardo-Gonzalez R., Goforth M., et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447 (2007) 1116-1120
26. Ogawa S., Lozach J., Jepsen K., et al. A nuclear receptor corepressor transcriptional checkpoint controlling activator protein 1-dependent gene networks required for macrophage activation. Proc Natl Acad Sci U S A 101 (2004) 14461-14466
27. Pascual G., Fong A., Ogawa S., et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437 (2005) 759-763
28. Patel C., Wyne K., and McGuire D. Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?. Diab Vasc Dis Res 2 (2005) 61-66
29. Perissi V., Aggarwal A., Glass C., et al. A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors. Cell 116 (2004) 511-526
30. Perkins N., Felzien L., Betts J., et al. Regulation of NF-kB by cyclin-dependent kinases associated with the p300 coactivator. Science 275 (1997) 523-527
31. Porcheray F., Viaud S., Rimaniol A., et al. Macrophage activation switching: an asset for the resolution of inflammation. Clin Exp Immunol 142 (2005) 481-489
32. Renaud J., and Moras D. Structural studies on nuclear receptors. Cell Mol Life Sci 57 (2000) 1748-1769
33. Ricote M., Huang J., Fajas L., et al. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Nat Acad Sci U S A 95 (1998) 7614-7619
34. Ricote M., Li A., Willson T., et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
35. Schopfer F., Lin Y., Baker P., et al. Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand. Proc Nat Acad Sci U S A 102 (2005) 2340-2345
36. Tacke F., Alvarez D., Kaplan T., et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest 117 (2007) 185-194
37. Tontonoz P., Nagy L., Alvarez J., et al. PPARg promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93 (1998) 241-252
38. Xu H., Lambert M., Montana V., et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 3 (1999) 397-403
39. Yu C., Markan K., Temple K., et al. The nuclear receptor corepressors NCoR and SMRT decrease peroxisome proliferator-activated receptor γ transcriptional activity and repress 3T3-L1 adipogenesis. J Biol Chem 280 (2005) 13600-13605
40. Zhang G., and Ghosh S. Molecular mechanisms of NF-kappaB activation induced by bacterial lipopolysaccharide through Toll-like receptors. J Endotoxin Res 6 (2000) 453-457